Complications and Pathophysiology of COVID-19 in the Nervous System

Haiyang Yu¹, Tong Sun² and Juan Feng*¹

¹ Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China, ² Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global public health threat. Majority of the patients with COVID-19 have fever, cough, and fatigue. Critically ill patients can develop dyspnea and acute respiratory distress syndrome. In addition to respiratory symptoms, neurological damage also occurs in some patients. However, the mechanisms by which SARS-CoV-2 invades the nervous system have not been elucidated yet. In order to provide some reference for designing optimal therapeutic strategies, we have discussed the complications and potential mechanisms of COVID-19 in the nervous system in this review.

Keywords: coronavirus, COVID-19, SARS-CoV-2, nervous system, complication, pathophysiology

INTRODUCTION

Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide (1). Because of the rapid spread of the virus and a sharp increase in the number of confirmed cases, the World Health Organization declared it a pandemic on March 11, 2020.

To date, seven human coronaviruses have been known to infect humans, three of which have resulted in epidemics (2, 3). First, the severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), started in Asia and then spread across the world in 2002 and 2003 (4). This was followed by the Middle East respiratory syndrome (MERS), caused by the MERS coronavirus (MERS-CoV), with a high mortality rate in 2012 (5). The current COVID-19 pandemic is the third and is still attracting global attention.

SARS-CoV-2 is considered a member of the beta coronaviruses (β-CoVs) family, which also contains SARS-CoV and MERS-CoV (6). The CoV family consists of enveloped, positive-sense single-stranded RNA viruses. They are spherical or oval in shape with large glycoprotein spikes on the surface and display a typical crown-like shape on negative staining when observed by electron microscopy. The CoV family is divided into four subfamilies genotypically and serologically, namely, α, β, γ, and δ-CoVs. Among them, α- and β-CoVs can cause human infection (7). Generally, all human CoVs are zoonotic, and bats are the most likely natural hosts of CoVs (8). Moreover, before CoVs infect humans, they need intermediate animal hosts of CoVs, which are civet cats and dromedary camels for SARS-CoV and MERS-CoV, respectively (9, 10). The discovery of pangolin CoVs and their similarity to SARS-CoV-2 indicate that pangolins may be the possible intermediate hosts for SARS-CoV-2 (11).

Currently, patients with COVID-19 are the main sources of infection. However, asymptomatic carriers have also been proven to excrete the virus and may be potential sources of infection (12). Respiratory droplets and close contact are regarded as the main transmission routes. It has been reported that SARS-CoV-2 may be isolated from the feces and urine. Therefore, attention should
COVID-19 mainly manifests with fever, dry cough, and fatigue. Few patients have symptoms of a stuffy or runny nose, headache, myalgia, and diarrhea. Most of the critically ill patients develop dyspnea or hypoxia 1 week after the onset of illness. With rapid progression of the disease, acute respiratory distress syndrome (ARDS), septic shock, and metabolic acidosis can develop (19). According to the pathological findings from limited autopsies and biopsies, SARS-CoV-2 can invade multiple tissues and organs in addition to the lung, such as the spleen, liver, heart, kidney, and brain (20, 21). Autopsy results have revealed that SARS-CoV-2 RNA could be detected in the brain tissue in 36.4% of fatal cases, which indicates the neurotropism and potential for invasion of SARS-CoV-2 in the brain (22). Recently, Zhang et al. were the first to prove that SARS-CoV-2 could directly infect induced pluripotent stem cells–derived human neural progenitor cells, and extensive viral replication and viral particles were detected in the neurospheres and brain organoids with SARS-CoV-2 infection. Additionally, they showed that SARS-CoV-2 could productively infect the human brain (23). A retrospective case series demonstrated that the neurological symptoms include central nervous system (CNS) symptoms or diseases (headache, dizziness, impaired consciousness, ataxia, acute cerebrovascular disease, and epilepsy), peripheral nervous system (PNS) symptoms (hyposmia, hypogeusia, hypopsia, and neuralgia), and skeletal muscle symptoms (24). In this review, we have discussed the principal COVID-19–related complications and pathophysiology in the nervous system (Table 1, Figure 1).

COVID-19–RELATED COMPLICATIONS IN THE NERVOUS SYSTEM

COVID-19–Related Complications in CNS

Viral Meningitis/Encephalitis

Viral infection can cause both meningitis and encephalitis, which are inflammation of the meninges and brain parenchyma, respectively (56). A man with COVID-19 exhibited meningeal irritation signs (nuchal rigidity, Kernig sign, and Brudzinski sign), along with positive extensor plantar response. After excluding bacterial or tuberculous infections of the CNS, SARS-CoV-2 encephalitis was diagnosed. However, SARS-CoV-2 in the CSF specimen was negative, which might be due to the extremely low titer of the virus in the CSF, or due to the lack of a standardized test for SARS-CoV-2 detection in the CSF (25). In Japan, a case report described the first patient who was sent to the emergency department because of a convulsion accompanied by unconsciousness and who was subsequently diagnosed with aseptic encephalitis with the SARS-CoV-2 RNA detected in the CSF (26). Similarly, in Los Angeles, a young woman with COVID-19 showed symptoms of meningoencephalitis without respiratory failure, and SARS-CoV-2 was found to be positive in the CSF by reverse transcription–polymerase chain reaction (PCR) (27, 28). In addition, two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection were reported in Switzerland, and a case of rhombencephalitis was reported as a rare complication of acute COVID-19 infection in the United Kingdom (29, 30).

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is an idiopathic CNS demyelinating disease, which is often postviral and is common in children, although it can occur at any age. The first case of COVID-19–related ADEM was reported in a 40-year-old man, and magnetic resonance imaging (MRI) revealed fluid-attenuated inversion recovery (FLAIR) hyperintensities in the subcortical and deep white matter (31). A 51-year-old woman developed a coma and impaired unilateral oculofacial response weeks after a SARS-CoV-2 infection. Her MRI demonstrated acute multifocal demyelinating lesions, and the clinical examination and CSF analysis were consistent with an acute demyelinating event (32). Furthermore, the autopsy of a 71-year-old patient diagnosed with COVID-19 showed scattered clusters of macrophages, axonal injury, and a perivascular ADEM-like appearance in the subcortical white matter (33).

Encephalopathy

In a retrospective study of 113 deceased patients with COVID-19, Chen et al. reported that 20% of cases demonstrated hypoxic encephalopathy, which is a higher proportion when compared with recovered patients (34). Elderly patients with chronic conditions are more susceptible to COVID-19, and patients with prior neurological conditions and acute respiratory symptoms are at an increased risk of encephalopathy. A 74-year-old man presented with symptoms of encephalopathy including headache and altered mental status and was diagnosed with COVID-19. As the CSF examination was normal, the neurological symptoms were not due to meningitis or encephalitis (35). Similarly, a 72-year-old man also presented with COVID-19 infection and encephalopathy. Subsequent CSF studies showed no evidence of a CNS infection. However, electroencephalography (EEG) revealed diffuse slowing consistent with an encephalopathy (36).

Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; ARDS, Acute respiratory distress syndrome; CNS, Central nervous system; PNS, Peripheral nervous system; ADEM, Acute disseminated encephalomyelitis; ANE, Acute necrotizing encephalopathy; ANM, Acute necrotizing myelitis; GBS, Guillain–Barre syndrome; MSF, Miller Fisher syndrome; BBB, Blood–brain barrier; PCR, Polymerase chain reaction; ACE2, angiotensin-converting enzyme 2.
TABLE 1 | Clinical manifestations and auxiliary examination findings of COVID-19 related complications in the nervous system.

| Complication | Clinical manifestations | Auxiliary examination | References |
|--------------|-------------------------|-----------------------|------------|
| **COVID-19-RELATED COMPLICATIONS IN THE NERVOUS SYSTEM** | | | |
| Viral meningitis/encephalitis | Headache | CSF: positive PCR assay for SARS-CoV-2 | (25–30) |
| | Altered mental status, meningeal irritation signs | Increased lymphocytes and proteins MRI: FLAIR hyperintensity EEG: slowing | |
| Acute disseminated encephalomyelitis (ADEM) | Multifocal deficits | MRI: FLAIR hyperintensity, multifocal demyelinating lesions | (31–33) |
| | | Autopsy: ADEM-like appearance in the subcortical white matter | |
| Encephalopathy | Headache, altered mental status | CSF: negative PCR assay for SARS-CoV-2 EEG: diffuse slowing | (34–36) |
| Acute necrotizing encephalopathy (ANE) | Altered mental status | CT: hypopattenuation MRI: T2 FLAIR hyperintensity with internal hemorrhage | (37) |
| Cerebrovascular disease | Sensory or motor dysfunction | CT/MRI: ischemic or hemorrhagic change | (38–40) |
| Epilepsy | Seizures | CSF: negative PCR assay for SARS-CoV-2 EEG: semirhythmic, irregular, high-amplitude delta waves | (41–43) |
| Acute myelitis | Flaccid paralysis, hypesthesia Urinary and bowel dysfunction | MRI: T2 hyperintensity | (31, 44, 45) |
| Hyposmia and hypogeusia | Loss of a sense of smell and taste | Questionnaire-based survey Cross-sectional study | (46–49) |
| Guillain-Barré syndrome (GBS) | Flaccid paralysis | MRI: enhancement of affected nerve roots EMG: decreased recruitment | (50–53) |
| Miller Fisher syndrome (MSF) | Ophthalmoplegia, ataxia, and areflexia | MRI: relative enlargement, T2 hyperintensity, and enhancement of the affected CN Anti-GD1b antibody positive | (54, 55) |

COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; EEG, electroencephalography; EMG, electromyography.

**Acute Necrotizing Encephalopathy**

Notably, Poyiadji et al. reported the first case of SARS-CoV-2 infection associated with acute hemorrhagic necrotizing encephalopathy. Acute necrotizing encephalopathy (ANE) is a rare encephalopathy that has been associated with influenza or other viral infections, which results in breakdown of the blood–brain barrier (BBB), without direct viral invasion or parainfectious demyelination. Imaging features are characterized by multifocal symmetric lesions in the thalami. However, the brain stem, cerebral white matter, and cerebellum may also be affected (37).

**Cerebrovascular Disease**

Cerebrovascular disease has been associated with an increased disease severity in patients with COVID-19 (38), and is also emerging as an important complication of COVID-19. Mao et al. reported that patients with a severe infection were more likely to develop neurological manifestations later in the course of the illness, especially acute cerebrovascular disease and impaired consciousness (24). However, Avula et al. reported four patients with PCR-confirmed SARS-CoV-2 infection, who presented with an acute ischemic stroke, and all four cases presented with a cerebrovascular accident in a relatively early stage of the illness (39). Moreover, two cases of cerebral hemorrhage have been reported by Al Saiegh et al. (40).

**Epilepsy**

In Italy, Vollono et al. reported a patient with COVID-19 whose primary symptom was a focal status epilepticus in the context of a predisposing but well-controlled postencephalitic epilepsy. Although the patient exhibited no fever or respiratory symptoms, the diagnostic hypothesis of a SARS-CoV-2 infection could be made on the basis of the worsening or recurrence of paroxysmal neurological events. Therefore, it is possible to hypothesize that SARS-CoV-2 could trigger seizures through a neurotropic pathogenic mechanism (41). However, a man without any history of epilepsy developed multiple episodes of seizures after infection with SARS-CoV-2 (42). In addition, an infant with both COVID-19 and rhinovirus infections also presented with seizures, although no changes were observed in the EEG (43).

**Spinal Cord Injury**

Besides involvement of the brain, SARS-CoV-2 can also damage the spinal cord. On admission to hospital, a 66-year-old man with COVID-19 presented with acute flaccid paralysis of bilateral lower limbs and urinary and bowel incontinence. He was diagnosed with postinfectious acute myelitis (31). In addition, a case of multifocal transverse myelitis has also been reported. After recovering from COVID-19, a 60-year-old man developed progressive weakness of the lower limbs and bladder dysfunction. Two days later, he showed hypesthesia below the Th9 level and a moderate spastic paraparesis. MRI of the spine revealed T2
signal hyperintensity of the thoracic spinal cord at the Th9 level, suggesting acute transverse myelitis (44). Moreover, a 69-year-old woman was diagnosed with acute necrotizing myelitis (ANM) based on the clinical symptoms and MRI manifestations (45).

COVID-19–Related Complications in the PNS

Hyposmia and Hypogeusia

In many countries, patients with COVID-19 have reported a loss of the sense of smell and taste. In South Korea, hyposmia was quite frequent among patients with mild COVID-19, and accompanying symptoms such as hypogeusia appeared in most of the patients with hyposmia (46). In Italy, a cross-sectional survey proved that olfactory and taste disorders were present in the early stages of the SARS-CoV-2 infection (47). Furthermore, researchers from France noticed that hyposmia and hypogeusia were reported during the early phase of the COVID-19 outbreak, and they investigated the utility of these symptoms for the early diagnosis of COVID-19 (48). Therefore, for patients with mild and inconspicuous symptoms and those in the early phase of illness, social distancing should be strongly implemented to prevent disease transmission (49).

Guillain-Barré Syndrome and Its Variants

Guillain-Barré syndrome (GBS) is an autoimmune-induced neuropathy, which mainly targets the peripheral nerves and their spinal roots. It is usually caused by an infection or immune stimulation that induces an aberrant autoimmune response (57). Several cases of GBS have been reported in patients with COVID-19 (50–53). However, additional epidemiological data are necessary to support a causal relationship between GBS and COVID-19.

Miller Fisher syndrome (MSF) is a variant of GBS and is an acute peripheral neuropathy that is manifested with a triad of ophthalmoplegia, ataxia, and areflexia. A 36-year-old man infected with SARS-CoV-2 showed diplopia due to cranial nerve (CN) III palsy. MRI revealed relative enlargement, T2 hyperintensity, and enhancement of the affected CN III (54). Similarly, a 50-year-old man presented with the triad of MSF and was positive for one of the antibodies to gangliosides (GD1b antibodies) (55).

COVID-19–RELATED PATHOPHYSIOLOGY IN THE NERVOUS SYSTEM

Direct Invasion

CoVs can invade the CNS through direct hematogenous and neural propagation (58). In case of hematogenous dissemination, CoVs in the airways can pass through the epithelial barrier reaching the blood or lymph circulation and then propagate toward the CNS. The BBB is composed of endothelial cells that interact with pericytes, astrocytes, microglia, and neurons in the

[Diagram: Complications and pathophysiology of COVID-19 in the nervous system]
neurovascular unit and regulate the permeability of the BBB and consequently maintain the integrity of the CNS (59). The diameter of the SARS-CoV-2 is 60–140 nm, making it easy for the virus to bypass the BBB and gain entry into the CNS (60).

The other route for invasion by the CoVs into the CNS is through neural dissemination, possibly by the polarization of neurons. This transport can be retrograde or antegrade and is facilitated by dynein and kinesin (61). Hyposmia in patients with COVID-19 may due to “conductive” loss or “neural” loss (62). Rapid recovery of normal olfaction in patients suggests a “conductive” loss, called olfactory cleft syndrome, and is associated with mucosal obstruction of the olfactory cleft (63). Fodoulian et al. showed that angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 are predominantly expressed in the non-neuronal cells of the olfactory epithelium and olfactory bulb in both mice and humans (64). Recently, neuropilin-1 (NRP1) was found to be expressed in the olfactory epithelium. Therefore, both ACE2 and NRP1 may be involved in the transmission of SARS-CoV-2 from the olfactory nerves to the CNS (65). Additionally, Wang et al. reported that SARS-CoV-2 could infect mature and immature olfactory neurons along with the supporting sustentacular cells in hamsters, and this may contribute to the unique olfactory dysfunction of COVID-19 (66). Although the olfactory bulb is important in early virologic control, several studies have proven that the olfactory route is an important pathway for viral entry into the CNS (67).

Angiotensin-Converting Enzyme 2
Similar to the SARS-CoV, SARS-CoV-2 can infect humans by targeting ACE2 via its spike protein. SARS-CoV-2 displays more specificity in recognizing ACE2 and has a stronger binding affinity with ACE2 due to the presence of a receptor-binding domain (68). ACE2 has multiple physiological roles, such as cell proliferation, blood pressure regulation, and inflammatory response. ACE2 is widely expressed in the lungs, kidneys, guts, cardiovascular system, and even the CNS, indicating that SARS-CoV-2 may affect multiple organs and systems (69).

In the brain, ACE2 is expressed in the neurons, astroglia cells, microglia cells, and endothelial cells (70). ACE2 is a negative regulator of the renin–angiotensin system, all components of which are present in the brain (71). Depletion of ACE2 increases the expression of angiotensin II, leading to vasoconstriction, sodium and water retention, elevated blood pressure, proinflammatory, and procoagulation effects (72). As SARS-CoV-2 binds to ACE2, some patients may demonstrate unusually high blood pressure and an increased risk of acute cerebrovascular disease. Given that SARS-CoV-2 targets ACE2 as the receptor, preventing the binding of SARS-CoV-2 with ACE2 may be a potential therapeutic strategy for preventing damage to multiple organs (73).

Hypoxic Injury
Severe patients with COVID-19 may develop ARDS, characterized by a serious shortness of breath and hypoxemia (19). The neuro-invasive potential of SARS-CoV2 may play a role in the respiratory failure seen in patients with COVID-19 (74). Hypoxia can cause a series of pathological changes in multiple organs. Pathological findings of COVID-19 associated with ARDS show pulmonary edema with hyaline membrane formation, which can lead to gas exchange disorders and hypoxia in the CNS (21). Hypoxia induces an excessive accumulation of anaerobic metabolites in the mitochondria and acid metabolites in brain, leading to edema of the brain cells and obstruction of the cerebral blood flow (75). The guidelines for the diagnosis and treatment of COVID-19 (trial version 8 in Chinese) (Supplementary Material 1) described the pathological changes consisting of brain congestion, edema, and degeneration of a part of the neurons on autopsy, which are similar to those seen in infection with SARS (76). Thus, severe hypoxia may be a high-risk factor for hypoxic encephalopathy and ischemic stroke, causing serious damage to the nervous system.

Coagulopathy
Zhang et al. reported that coagulopathy and antiphospholipid antibodies were present in three patients with COVID-19 (77). Moreover, a retrospective analysis revealed that abnormal coagulation results, including markedly elevated D-dimer and fibrin degradation product levels, as well as a longer prothrombin time and activated partial thromboplastin time, are associated with poor prognosis. Additionally, disseminated intravascular coagulation is more commonly associated with COVID-19 deaths (78). The hypercoagulability seen in patients with COVID-19 may predispose to a stroke (79). Consequently, anticoagulant treatment may decrease the mortality in severe COVID-19 patients with coagulopathy (80).

Inflammatory Response
ARDS is the principal cause of death in patients with COVID-19 (19). One of the main mechanisms of ARDS is a cytokine storm, which is a deadly systemic inflammatory response, characterized by the release of large amounts of proinflammatory cytokines and chemokines by immune effector cells, including interleukin 2 (IL-2), IL-6, IL-7, IL-10, and IL-1β, as well as interferon γ, tumor necrosis factor α (TNF-α), GCSF, IP10, MCP1, and MIP1A (19, 81). Cytokine storm can induce an immune attack in the body, causing multiple organ failure and ARDS (82). Additionally, previous studies have shown that the coronavirus can induce proinflammatory cytokine signals from astrocytes and microglia cells, releasing a large amount of inflammatory factors such as IL-6, IL-12, IL-15, IL-1β, and TNF-α. This is also one of the pathophysiological processes responsible for CNS damage caused by inflammatory factors (83). Given the substantial increase in the proinflammatory cytokines, therapies such as plasma exchange and the IL-6 receptor-targeted monoclonal antibody are used to ameliorate the inflammatory response (84, 85). Furthermore, Lianhuamingwen, a traditional Chinese medicine, has been proven to exert anti-inflammatory activity against SARS-CoV-2 in vitro (86).

Immune Dysfunction
In severe patients with COVID-19, peripheral CD4+ T and CD8+ T cell numbers are significantly reduced, although they are in a hyperactivated state. Moreover, there are high concentrations of proinflammatory CCR6+ T, hT17 in CD4+ T cells.
T cells and cytotoxic granules in CD8+ T cells, suggesting that the overactivation of T cells is associated with immune injury in severe patients (21). In addition, a significant and progressive decrease in the lymphocytes is considered a sign of severity (87). Neutralizing antibodies in convalescent plasma were used to treat five critically ill patients with COVID-19 and ARDS, and their clinical status improved (88). However, Wang et al. found that severe patients had an increased immunoglobulin G (IgG) response and higher levels of IgG, especially anti–spike IgG (anti–S-IgG) neutralizing antibodies (89). This suggested that antibody-dependent enhancement (ADE) was present in SARS-CoV-2 infection, similar to what has been observed in multiple viral infections (90). ADE can promote cellular uptake of virus–antibody complexes (virus–anti–S-IgG) by interacting with the Fc receptor or other receptors, leading to enhanced invasion of the virus (91). Therefore, immune system can be activated by a viral infection, and activation of the immune cells in the brain may cause chronic inflammation and neurological damage (92). Furthermore, immune dysfunction after SARS-CoV-2 infection can result in a series of postinfectious diseases, such as ADEM, ANE, ANM, and GBS and its variants.

**DISCUSSION**

The pandemic of COVID-19 has become a global concern, and the respiratory system is not the only system involved in this disease. In this review, we discussed the main neurological complications and potential mechanisms of COVID-19. Neurological manifestations including hyposmia and hypogeusia may be the first symptoms of COVID-19 and may help in early detection, diagnosis, isolation, and treatment. With disease progression, more severe neurological symptoms may appear in critically ill patients, such as encephalitis, encephalopathy, and acute cerebrovascular disease. Nevertheless, the full clinical spectrum of neurological symptoms in patients with COVID-19 remains to be characterized. Neurologists should pay attention to these neurological manifestations and follow them up for possible neurological sequelae. It is exciting to see that several vaccines for COVID-19 are in clinical trials (NCT04398147; NCT04456595; NCT04466085; NCT04368728), although there are still no effective drugs to treat COVID-19 (93). Therefore, people across the world still need to make a huge effort to combat the COVID-19 pandemic.

**AUTHOR CONTRIBUTIONS**

JF conceived and revised this review. HY took charge of the original manuscript writing. TS drew the figure and table. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the doctors, nurses, scientists, and volunteers on the front lines of the fight against COVID-19.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.573421/full#supplementary-material

**REFERENCES**

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med.* (2020) 382:1199–207. doi: 10.1056/NEJMoA2001316.
2. Decaro N, Lorusso A. Novel human coronavirus (SARS-CoV-2): a lesson from animal coronaviruses. *Vet Microbiol.* (2020) 244:108693. doi: 10.1016/j.vetmic.2020.108693.
3. Guarner J. Three emerging coronaviruses in two decades. *Am J Clin Pathol.* (2020) 153:420–1. doi: 10.1093/ajcp/aqaa029.
4. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, et al. SARS—beginning to understand a new virus. *Nat Rev Microbiol.* (2003) 1:209–18. doi: 10.1038/nrmicro7775.
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med.* (2012) 367:1814–20. doi: 10.1056/NEJMoa1211721.
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a novel coronavirus of probable bat origin. *Nature.* (2020) 579:270–3. doi: 10.1038/s41586-020-0212-7.
7. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9.
8. Corman VM, Muth D, Niemeyer D, Drosten C. Chapter eight - hosts and sources of endemic human coronaviruses. In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. *Adv Virus Res.* Berlin: Academic Press (2018). p. 163–88. doi: 10.1016/bs.avir.2018.01.001.
9. Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat Med.* (2004) 10(12 Suppl.):S88–97. doi: 10.1038/nm1143.
10. Chu DKW, Poon LLM, Gomaa MM, Shehata MM, Perera RAPM, Abu Zeid D, et al. MERS coronaviruses in dromedary camels, Egypt. *Emerging Infect Dis.* (2014) 20:1049–53. doi: 10.3201/eid2006.140299.
11. Lam TTY, Jia N, Zhang YW, Shum MHH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. *Nature.* (2020) 583:282–5. doi: 10.1038/s41586-020-2169-0.
12. Hoeih S, Rabenu H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. *N Engl J Med.* (2020) 382:1278–80. doi: 10.1056/NEJMc2001899.
13. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. *Gastroenterology.* (2020) 158:1518–9. doi: 10.1053/j.gastro.2020.02.054.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3.
15. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. *Lancet Oncol.* (2021) 22:893–903. doi: 10.1016/S1470-2241(20)30309-0.
16. Zhang J, Wang C, Ai X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect.* (2020) 26:767–72. doi: 10.1016/j.cmi.2020.04.012.
17. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* (2020) 146:110–8. doi: 10.1016/j.jaci.2020.04.006.
18. Leung JM, Sin DD. Smoking, ACE-2 and COVID-19: ongoing controversies. *Eur Respir J.* (2020) 56:2001759. doi: 10.1183/13993003.01759-2020
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
20. Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. *Biomol Therapeutics.* (2020) 12:119015. doi: 10.4103/bioph.2020.119015
21. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* (2020) 8:420–2. doi: 10.1016/S2213-2600(20)30076-X
22. Puelles VG, Lütgehmett M, Lindenmeyer MT, Sperhake JP, Wong MN, et al. Multiorgan and renal tropism of SARS-CoV-2. *N Engl J Med.* (2020) 383:590–2. doi: 10.1056/NEJMoa2001440
23. Zhang RZ, Chu H, Han S, Shuai H, Deng J, Hu YF, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. *Cell Res.* (2020) 30:928–31. doi: 10.1038/s41422-020-0390-x
24. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *JAMA Neurol.* (2020) 77:683–90. doi: 10.1001/jamaneurol.2020.1127
25. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. *Brain Behav Immun.* (2020) 87:55–8. doi: 10.1016/j.bbi.2020.04.024
26. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. *Int J Infect Dis.* (2020) 94:55–8. doi: 10.1016/j.ijid.2020.03.062
27. Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in downtown los angeles, early April 2020. *Brain Behav Immun.* (2020) 87:33. doi: 10.1016/j.bbi.2020.04.017
28. Huang YH, Jiang D, Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. *Brain Behav Immun.* (2020) 87:149. doi: 10.1016/j.bbi.2020.05.012
29. Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser E, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. *J Neurol Neurosurg Psychiatry.* (2020) 91:846–8. doi: 10.1136/jnnp-2020-332522
30. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidesi S, Horgetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. *Seizure.* (2020) 78:109–12. doi: 10.1016/j.seizure.2020.04.009
31. Sohal S, Mossammat M. COVID-19 presenting with seizures. *IDCases.* (2020) 20:100782. doi: 10.1016/j.idc.2020.04.009
32. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
33. Yu et al. COVID-19 in Nervous System
34. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute complications of acute COVID-19 infection. *Acta Neuropathol.* (2020) 140:1–6. doi: 10.1007/s00401-020-02165-w
35. Da Costa J, Rodriguez-Álvarez Y. COVID-19-associated acute necrotizing myelitis. *Neuro Neuroinmunol Neuroinflamm.* (2020) 7:e803. doi: 10.1212/NXI.0000000000000803
36. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect.* (2020) 26:948.e1–3. doi: 10.1016/j.cmi.2020.04.040
37. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. *Clin Infect Dis.* (2020) 71:889–90. doi: 10.1093/cid/ciaa330
38. Bénétif F, Le Turnier P, Declercq C, Paillé C, Revest M, Dubé V, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. *Lancet Infect Dis.* (2020) 20:1014–5. doi: 10.1016/S1473-3099(20)30297-8
39. Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. *RhinoLOGY.* (2020) 58:295–8. doi: 10.4193/Rhinol.2020
40. Sedaghat Z, Karimi N. Guillain barre syndrome associated with COVID-19 infection: a case report. *J Clin Neurosci.* (2020) 76:233–5. doi: 10.1016/j.jocn.2020.04.062
41. Virani A, Babol J, Haq M, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. *IDCases.* (2020) 20:00771. doi: 10.1016/j.idc.2020.07711
42. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré syndrome associated with SARS-CoV-2. *N Engl J Med.* (2020) 382:2574–6. doi: 10.1056/NEJMoa2009191
43. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol.* (2020) 19:383–4. doi: 10.1016/S1474-4422(20)30109-5
44. Lantos JE, Strauss SB, Lin E. COVID-19-associated miller fisher syndrome: MRI findings. *AJNR Am J Neuroradiol.* (2020) 41:1184–6. doi: 10.3174/ajnr.A6609
45. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodríguez-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller fisher syndrome and polynейritis cranialis in COVID-19. *Neurology.* (2020) 95:e601–5. doi: 10.1212/WNL.0000000000009619
46. Meyfroidt G, Kurtz P, Sonneville R. Critical care management of infectious meningitis and encephalitis. *Intensive Care Med.* (2020) 46:192–201. doi: 10.1007/s00134-019-05901-w
47. Willson HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet.* (2016) 388:717–27. doi: 10.1016/S0140-6736(16)30393-1
48. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot CF. Neuropathology of COVID-19: viral and cellular factors involved in neurinvasiveness and neuropathogenesis. *Virus Res.* (2014) 194:145–58. doi: 10.1016/j.virusres.2014.09.011
49. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalli D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. *Acta Neuropathol.* (2018) 135:311–36. doi: 10.1007/s00401-018-1815-1
50. Alam SB, Willows S, Kulka M, Sandhu JK. Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system. *Eur J Neurol.* (2020) doi: 10.1111/ene.14442. [Epub ahead of print].
61. Desforges M, Le Coupanc A, Dubeau P, Bourguin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. (2019) 12:124. doi: 10.3390/v12010014

62. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. (2020) 58:299–301. doi: 10.4193/Rhinol20.114

63. Trotier D, Bensimon JL, Herman P, Tran Ba Huy P, Eloit C. Inflammatory obstruction of the olfactory clefts and olfactory loss in humans: a new syndrome? Chem Senses. (2007) 32:285–92. doi: 10.1093/chemse/bjl057

64. Fodoulian L, Tubeross J, Rossier D, Boillot M, Kan C, Pauli V, et al. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium. bioRxiv [Preprint]. (2020). doi: 10.1101/2020.05.31.013268

65. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djanntian M, Franz J, Kuivanan S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. bioRxiv [Preprint]. (2020). doi: 10.1101/2020.06.07.137802

66. Zhang AJ, Lee ACY, Chu H, Chan JFW, Fan Z, Li C, et al. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium. bioRxiv [Preprint]. (2020). doi: 10.1101/2020.06.07.137802

67. Durrant DM, Ghosh S, Klein RS. The olfactory bulb: an immunosensory organ? ACS Chem Neurosci. (2020) 11:322–5. doi: 10.1021/acschemneuro.9b00109

68. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis. (2020) 15:ciaa995. doi: 10.1093/cid/ciaa995

69. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis

70. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. ACE2/ANG-(1–7)/Mas pathway in the brain: a new syndrome? Clin Sci. (2019) 135:661–8. doi: 10.1042/CS20190350

71. Gironacci MM, Cerniello FM, Longo Carbajosa NA, Goldstein J, Cerrato BD. Differential expression of neuronal ACE2 in transgenic mice with a transgenic model of Alzheimer’s disease. J Exp Med. (2005) 202:415–24. doi: 10.1084/jem.20050828

72. Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1–7)/Mas pathway in the brain: a new syndrome? Clin Sci. (2019) 135:661–8. doi: 10.1042/CS20190350

73. Ghebrial M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. (2007) 292:R373–81. doi: 10.1152/ajpregu.00292.2006

74. Gironacci MM, Cerniello FM, Longo Carbajosa NA, Goldstein J, Cerrato RD. Protective axis of the renin-angiotensin system in the brain. Clin Sci. (2014) 126:295–306. doi: 10.1042/CS20140350

75. Abdennour L, Zeghal C, Dème M, Puybasset L. Interaction brain-lungs. Rev Med Virol. (2020) 30:266–71. doi: 10.1002/jmv.25728

76. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. (2005) 202:215–4. doi: 10.1084/jem.20050828

77. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. (2020) 382:e38. doi: 10.1056/NEJMc2007575

78. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. (2020) 18:844–7. doi: 10.1111/jth.14768

79. Hess DC, Eldahshan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res. (2020) 11:322–5. doi: 10.1007/s12975-020-00818-9

80. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094–9. doi: 10.1111/jth.14817

81. Shi Y, Tan M, Chen X, Liu Y, Huang J, Ou J, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. (2020) 160:255–8. doi: 10.1111/1348-5037.14373

82. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. (2020) 10:102–8. doi: 10.1016/j.jpha.2020.03.001

83. Li Y, Fu L, Gonzales DM, Lavi E. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. J Virol. (2004) 78:3398–406. doi: 10.1128/JVI.78.7.3398–406.2004

84. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. (2020) 55:105954. doi: 10.1016/j.ijantimicag.2020.105954

85. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminating COVID-19. Crit Care. (2020) 24:128. doi: 10.1186/s13054-020-3836-4

86. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. (2020) 156:104761. doi: 10.1016/j.phrs.2020.104761

87. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. (2020) 95:834–47. doi: 10.1002/ajh.25829

88. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. (2020) 323:1582–9. doi: 10.1001/jama.2020.4783

89. Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. (2020) 7:157. doi: 10.3389/fmolb.2020.00157

90. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sinica. (2020) 35:266–71. doi: 10.1007/s12250-020-00207-4

91. Takaeda A, Kawaioka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. (2003) 13:387–98. doi: 10.1002/rmv.405

92. Klein RS, Garber C, Howard N. Infectious immunity in the central nervous system and brain function. Nat Immunol. (2017) 18:132–41. doi: 10.1038/ni.3656

93. Zha FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. (2020) 395:1845–54. doi: 10.1016/S0140-6736(20)32108-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.